Conception
Conception is a pre-clinical biotech developing in-vitro gametogenesis (IVG) technology to derive functional human egg cells from induced pluripotent stem cells, targeting individuals facing biological or medical infertility barriers as a future regulated therapy.
- Company typePrivate
- Founded2018
- HeadquartersBerkeley, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Conception does
Conception is an R&D-stage biotechnology company founded in 2018 and headquartered in Berkeley, California, developing in-vitro gametogenesis (IVG) technology to derive functional human egg cells from induced pluripotent stem cells (iPSCs). The company's core platform guides iPSCs through a defined multi-stage differentiation sequence — from Primordial Germ Cells and Oogonia through Ovarian Helper Cells and successive follicle stages (Primordial, Primary, Secondary, Antral) culminating in mature eggs — using a combination of stem cell biology, 3D organoid engineering, gene expression mapping, and high-throughput genetic screening with computer-vision quality scoring. The intended application is a regulated medical therapy for individuals facing biological or medical limits to fertility, including age-related egg supply decline, medical barriers to conception, and the broader global infertility crisis.
Conception has built a 40+ person cross-disciplinary team spanning stem cell biology, developmental biology, tissue engineering, and computation, led by CEO and co-founder Matthew Krisiloff, co-founder and Chief Scientific Officer Pablo Gonzalez, and co-founder and President Bianka Seres, alongside a Scientific Director and Principal Scientist. The company has raised approximately $20 million in disclosed funding, with its largest round in November 2021, alongside earlier seed checks from For Good Ventures, HOF Capital, and Compound.
The company has no commercial products, no revenue, and no disclosed pricing model. Its stated future revenue model is licensing and royalties on therapeutic applications of IVG technology, contingent on formal regulatory approval based on safety and efficacy data. Marketing is limited to a scientific website and mailing list, and there are no disclosed customers, partnerships, awards, or patents — the moat today resides in proprietary protocols, scientific talent, and accumulated wet-lab know-how rather than in commercial relationships or regulated assets.
Conception firmographics
Firmographics- Name
- Conception
- Legal name
- Conception
- Website
- https://conception.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Conception is a pre-clinical biotech developing in-vitro gametogenesis (IVG) technology to derive functional human egg cells from induced pluripotent stem cells, targeting individuals facing biological or medical infertility barriers as a future regulated therapy.
- Ownership category
- akta.pro rank
Conception industry classification
Industry- Product category
- Reproductive Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro industry
- Reproductive Endocrinology & Infertility (IVF/Fertility)
Keywords
Where Conception is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Conception business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Future Therapeutic Revenue: Conception is an R&D-stage biotech company developing in-vitro gametogenesis technology as a medical therapy. The company has no commercial products or revenue currently. Future revenue will come from therapeutic applications of its IVG technology pending regulatory approval.
Go-to-market motion1 record
Marketing channels2 records
Conception product offering
Product offeringCore offering
Conception is an R&D-stage biotechnology company developing in-vitro gametogenesis (IVG) technology that derives functional human egg cells from induced pluripotent stem cells (iPSCs). The platform uses stem cell biology, 3D organoid engineering, and computational analysis to guide cells through stages of reproductive development, aiming to deliver a regulated medical therapy for infertility. The company currently has no commercial products and is preparing its technology for future regulatory approval.
Product overview
Conception is developing an In-Vitro Gametogenesis (IVG) Platform that enables the derivation of functional eggs from stem cells. Their technology recreates the natural sequence of human reproductive development through stem cell biology, tissue engineering, and computation. The platform guides induced pluripotent stem cells (iPSCs) through multiple stages—from Primordial Germ Cells and Oogonia through Ovarian Helper Cells, various follicle stages (Primordial, Primary, Secondary, Antral), culminating in mature eggs capable of fertilization.
Differentiator
Problem solved
Functional benefit
Products and services
- In-Vitro Gametogenesis (IVG) Platform A stem cell technology platform that derives functional human egg cells from induced pluripotent stem cells (iPSCs), guiding cells through stages from primordial germ cells and oogonia through ovarian helper cells and successive follicle stages to mature eggs capable of fertilization. It is intended as a future medical therapy for individuals with biological or medical infertility barriers.
Quantifiable outcome
- Successfully derives functional eggs from stem cells through differentiation, progression, follicle formation, follicle growth, and egg maturation stages
Companies that use Conception
Customer profileSegments1 record
Ideal customer profiles1 record
Conception technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Conception partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Conception competitors and assessment
Company assessmentDirect peers
- Gameto: Gameto is a reproductive biotechnology company using cell engineering to develop ovarian cell therapies for fertility and menopause. It is the closest direct peer to Conception as both pursue stem-cell and developmental-biology approaches to female reproductive health.
Emerging players
- Ivy Natal: Ivy Natal is an early-stage reproductive biotech working on technologies relevant to egg health and IVF outcomes. Comparable as a niche emerging player pursuing biotechnology-based interventions in the fertility space alongside Conception.
- Celmatix: Celmatix is a precision-medicine company targeting ovarian biology and reproductive drug discovery. Comparable as a reproductive biotech applying genomics and biology to fertility, intersecting with Conception's R&D focus on oocyte biology.
- Orchid Health: Orchid offers embryo genetic screening to help parents reduce disease risk during IVF. It is comparable as an emerging biotech using advanced reproductive technology in the IVF workflow, addressing a related set of patients to Conception's future IVG-derived eggs.
Broad incumbents
- Kindbody: Kindbody operates a national network of fertility clinics and benefits programs offering IVF and related services. It is a broad incumbent serving the same end-customer (people needing fertility treatment) that Conception's future therapy would also serve.
- Progyny: Progyny is a leading fertility benefits management company that partners with employers to provide IVF and family-building coverage. It is comparable as a broad incumbent controlling access to fertility treatment channels that any future IVG therapy would need to reach patients through.
- Maven Clinic: Maven Clinic is a virtual women's and family health platform covering fertility, pregnancy, and postpartum care. Comparable as a broader incumbent in women's reproductive health where Conception's eventual therapy would compete for patient attention and payer coverage.
- Carrot Fertility: Carrot Fertility provides global fertility benefits and navigation services to employers. It is a broad incumbent in the fertility access and benefits layer that any future IVG therapy would need to integrate with for commercial uptake.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Conception social profiles
Digital presenceConception financial estimates
Financial estimateRevenue estimate
Valuation estimate
Conception leadership team
Management profileNumber of profiles
Profiles3 records
Conception funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Conception M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Conception
What does Conception do?
Conception is an R&D-stage biotechnology company developing in-vitro gametogenesis (IVG) technology that derives functional human egg cells from induced pluripotent stem cells (iPSCs). The platform uses stem cell biology, 3D organoid engineering, and computational analysis to guide cells through stages of reproductive development, aiming to deliver a regulated medical therapy for infertility. The company currently has no commercial products and is preparing its technology for future regulatory approval.
Is Conception a public or private company?
Conception is a private company. It is classified as venture growth investor backed and is currently operating.
When was Conception founded?
Conception was founded in 2018. It employs 51 to 100 people.
Where is Conception based?
Conception is headquartered in Berkeley, United States, in the North America region.
How does Conception make money?
One revenue line is on record: future Therapeutic Revenue.
Who are Conception's main competitors?
Gameto is listed as a direct peer. Emerging players are Ivy Natal, Celmatix and Orchid Health. Broad incumbents are Kindbody, Progyny, Maven Clinic and Carrot Fertility.
Does Conception have an API?
No public API is recorded for Conception.
What industry is Conception in?
Conception's product category is Reproductive Biotechnology. Its primary akta.pro industry code is HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 541714.